Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/12—Aerosols; Foams
  • A61K9/124—Aerosols; Foams characterised by the propellant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M15/00—Inhalators
  • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
  • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
  • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
  • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
  • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
  • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
  • B65B31/003—Adding propellants in fluid form to aerosol containers
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
  • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
  • B65B7/00—Closing containers or receptacles after filling
  • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
  • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
  • B65B7/2842—Securing closures on containers
  • B65B7/285—Securing closures on containers by deformation of the closure

Definitions

• the present invention relates to pharmaceutical aerosol solution formulations intended for use with pressurized metered dose inhalers.
• the present invention further relates to use of such formulations in the prevention and therapy of respiratory disorders, including chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• Glycopyrronium bromide also known as glycopyrrolate
• glycopyrrolate is a muscarinic M3 anticholinergic agent used to reduce salivation associated with administration of certain anaesthetics, and as adjunctive therapy for peptic ulcers. It has also been reported to be effective in the treatment of asthmatic symptoms (Hansel et al., Chest, 2005; 128:1974-1979).
• WO 2005/107873 discloses the use of glycopyrrolate for the treatment of childhood asthma.
• WO 01/76575 discloses a controlled release formulation for pulmonary delivery of glycopyrrolate.
• the formulation is intended for use in treatment of respiratory disease, in particular chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• the application focuses on dry powder formulations suitable for delivery by means of a dry powder inhaler (DPI).
• DPI dry powder inhaler
• WO 2005/074918 discloses combinations of glycopyrrolate with glucocorticoid drugs, and their use for treating diseases of the respiratory tract.
• WO 2005/110402 discloses combinations of glycopyrrolate and a beta-2 agonist of the class of indane or of benzothiazole-2-one derivatives for treatment of inflammatory or obstructive airway diseases.
• WO 2006/105401 discloses combinations of an anticholinergic, a corticosteroid and a long-acting beta-2 agonist for prevention and treatment of respiratory, inflammatory or obstructive airway diseases.
• the anticholinergic is optionally glycopyrrolate.
• combinations of glycopyrronium bromide respectively with an anti-inflammatory steroid and, in particular, with mometasone furoate provide a therapeutic benefit in the treatment of inflammatory and obstructive airways diseases.
• WO 2007/057221 and WO 2007/057219 disclose combinations of a glycopyrronium salt with an indanyl derivative beta-2 agonist (or analogue) and respectively with an anti-inflammatory steroid and, in particular, with mometasone furoate.
• Formoterol is a beta-2 agonist drug capable of relaxing smooth muscle in the bronchi and opening the airways to reduce wheezing conditions. It is commonly used in the management of asthma and other respiratory conditions.
• Foster® is designed for delivery by aerosol to the lungs using a pressurized metered dcse inhaler (pMDI). It has long been known that aerosol solutions of formoterol fumarate are relatively unstable and have a short shelf-life when stored under suboptimal conditions.
• the Foster® formulation incorporates a quantity of inorganic acid in order to stabilize the formoterol component (as described in EP 1157689).
• dissolved in HFA propellant and a co-solvent, wherein the formulation also comprises an inorganic acid as stabilizing agent are useful for the prevention and therapy of respiratory disorders, including COPD.
• the formulation further comprises beclometasone dipropionate.
• the present invention provides the use of a combination product comprising glycopyrronium bromide and formoterol or a salt thereof for the prevention or treatment of COPD and other respiratory diseases.
• the present invention provides methods for the prevention or treatment of COPD and other respiratory diseases by administering such a formulation to a subject in need thereof.
• the invention provides a canister for use with a pMDI comprising:
• the formulation also comprises an inorganic acid as stabilizing agent.
• glycopyrronium bromide is normally unstable in aerosol solution formulations based on HFA and co-solvent, but is stabilized by the inclusion of acid in the formulation.
• a further significant discovery is that removal of oxygen from the canister headspace further stabilizes formoterol in combination solution formulations with glycopyrronium bromide.
• Glycopyrronium bromide chemically defined as 3-[(cyclopentylhydroxy-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide, has two chiral centers corresponding to four potential different stereoisomers with configurations (3R,2′R), (3S,2′R), (3R,2′S), and (3S,2′S).
• Glycopyrronium bromide in the form of any of these pure enantiomers or diastereomers or any combination thereof may be used in practising the present invention.
• the (3S,2′R), (3R,2′S)-3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide racemic mixture, also known as glycopyrrolate is preferred.
• Glycopyrronium bromide is present in the formulation in an amount in the range from 0.005 to 0.14% (w/w), preferably from 0.010 to 0.13% (w/w), more preferably from 0.015 to 0.04% (w/w), wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• Glycopyrrolate is commercially available, and can be synthesized according to the process described in U.S. Pat. No. 2,956,062 or in Franko B V and Lunsford C D, J. Med. Pharm. Chem., 2(5), 523-540, 1960.
• the propellant component of the composition may be any pressure-liquefied propellant and is preferably a hydrofluoroalkane (HFA) or a mixture of different HFAs, more preferably selected from the group consisting of HFA 134a (1,1,1,2-tetrafluoroethane), HFA 227 (1,1,1,2,3,3,3-heptafluoropropane), and mixtures thereof.
• HFA hydrofluoroalkane
• HFAs may be present in the formulation in an amount in the range from 75 to 95% (w/w), preferably from 85 to 90% (w/w), wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• the formoterol component of the formulation can be in the form of the free base, or as a salt or a solvate.
• the formoterol is provided in the form of formoterol fumarate.
• Formoterol fumarate can, for instance, be employed in the formulation in an amount of 0.005 to 0.07% w/w, preferably 0.01 to 0.02% w/w, wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• the co-solvent incorporated into formulations of the invention has a higher polarity than that of the propellant and may include one or more substances such as a pharmaceutically acceptable alcohol, in particular ethanol, or a polyol such as propylene glycol or polyethylene glycol.
• the co-solvent is selected from the group of lower branched or linear alkyl (C 1 -C 4 ) alcohols such as ethanol and isopropyl alcohol.
• the co-solvent is ethanol.
• the concentration of the co-solvent will vary depending on the final concentration of the active ingredient in the formulation and on the type of propellant.
• ethanol may be used in a concentration comprised in the range from 5 to 25% (w/w), preferably from 8 to 20% (w/w), more preferably from 10 to 15% (w/w), wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• concentration of ethanol is 12% (w/w).
• the ratio of propellant to co-solvent in the formulation is in the range from 50:50 to 95:5 (w/w).
• HCl of different molarity or alternative inorganic acids could substitute for 1M HCl in the formulations of the invention.
• alternative acids could be any pharmaceutically acceptable monoprotic or polyprotic acid, such as (but not limited to): hydrogen halides (hydrochloric acid, hydrobromic acid, hydroiodic acid etc.) phosphoric acid, nitric acid, sulphuric acid, and halogen oxoacids.
• the pharmaceutically active components of the composition are substantially completely and homogeneously dissolved in the mixture of propellant and co-solvent, i.e. the composition is preferably a solution formulation.
• the solution formulation compositions may comprise other pharmaceutical excipients or additives known in the art.
• the compositions of the present invention may comprise one or more low volatility components. Low volatility components are useful in order to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles upon actuation of the inhaler and/or to improve the solubility of the active ingredient in the propellant/co-solvent mixture.
• MMAD mass median aerodynamic diameter
• the low volatility component when present, has a vapor pressure at 25° C. lower than 0.1 kPa, preferably lower than 0.05 kPa.
• low-volatility components are esters such as isopropyl myristate, ascorbyl myristate, tocopherol esters; glycols such as propylene glycol, polyethylene glycol, glycerol; and surface active agents such as saturated organic carboxylic acids (e.g. lauric, myristic, stearic acid) or unsaturated carboxylic acids (e.g. oleic or ascorbic acid).
• the amount of low volatility component may vary from 0.1 to 10% w/w, preferably from 0.5 to 5% (w/w), more preferably between 1 and 2% (w/w), wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• an amount of water comprised between 0.005 and 0.3% (w/w), wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition, may optionally be added to the formulations in order to favourably affect the solubility of the active ingredient without increasing the MMAD of the aerosol droplets upon actuation.
• the formulations of the present invention are free of excipients (such as surfactants) other than co-solvent, propellant, and a stabilizing amount of an acid.
• compositions of the present invention may further comprise other, additional pharmaceutically active agents for separate, sequential or simultaneous use.
• additional pharmaceutically active components of the composition include any known in the art for prophylaxis or treatment of respiratory diseases and their symptoms. Examples of these active components are: beta-2 agonists such as salbutamol, fenoterol, carmoterol (TA-2005), indacaterol, milveterol, vilanterol (GSK 642444), terbultaline, salmeterol, bitolterol, and metaproterenol in form of single stereoisomers or mixtures thereof and salts thereof; corticosteroids such as beclometasone dipropionate, fluticasone propionate, butixocort, mometasone furoate, triamcinolone acetonide, budesonide and its 22R-epimer, ciclesonide, flunisolide, loteprednol, and rofleponide; other anti-
• compositions of the present invention comprise beclometasone dipropionate (BDP) as active agent in addition to the formoterol and glycopyrrdnium bromide components.
• BDP is preferably present in the formulation in an amount of 0.07 to 0.41% w/w, preferably 0.1 to 0.3% w/w, wherein % (w/w) means the amount by weight of the component, expressed as percent with respect to the total weight of the composition.
• compositions of the present invention can be inhaled from any suitable pressurized MDI device known to the skilled person.
• Desired doses of the individual pharmaceutically active components of the formulation are dependent on the identity of the component and the type and severity of the disease condition, but are preferably such that a therapeutic amount of the active ingredient is delivered in one or two actuations.
• doses of active ingredient are in the range of about 0.5 to 1000 ⁇ g per actuation, e.g. about 1 to 100 ⁇ g/actuation, and sometimes about 5 to 50 ⁇ g/actuation.
• the skilled person in the field is familiar with how to determine the appropriate dosage for each individual pharmaceutically active ingredient.
• the preferred dosage is about 0.5 to 50 ⁇ g per actuation, preferably about 1 to 25 ⁇ g per actuation, and more preferably about 5 to 15 ⁇ g per actuation.
• the dose of formoterol fumarate is 6 or 12 ⁇ g/actuation.
• the preferred dosage is about 0.5 to 100 ⁇ g per actuation, preferably about 1 to 40 ⁇ g per actuation, and more preferably about 5 to 26 ⁇ g per actuation. In one specific embodiment the dose of glycopyrronium bromide is about 25 ⁇ g/actuation.
• the preferred dosage is about 10 to 2000 ⁇ g per actuation, preferably about 20 to 1000 ⁇ g per actuation, and more preferably about 50-250 ⁇ g per actuation. In specific embodiments the dose of beclometasone dipropionate is about 50, 100, or 200 ⁇ g/actuation.
• the pharmaceutical formulation of the present invention is filled into pMDI devices known in the art.
• Said devices comprise a canister fitted with a metering valve. Actuation of the metering valve allows a small portion of the spray product to be released.
• Part or all of the canister may be made of a metal, for example aluminum, aluminum alloy, stainless steel or anodized aluminum.
• the canister may be a plastic can or a plastic-coated glass bottle.
• the metal canisters may have part or all of their internal surfaces lined with an inert organic coating.
• preferred coatings are epoxy-phenol resins, perfluorinated polymers such as perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as poly-tetrafluoroethylene (Teflon), fluorinated-ethylene-propylene (FEP), polyether sulfone (PES) or fluorinated-ethylene-propylene polyether sulfone (FEP-PES) mixtures or combination thereof.
• Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
• canisters having their internal surface lined with FEP-PES or Teflon may be used.
• canisters made of stainless steel may be used.
• the container is closed with a metering valve for delivering a daily therapeutically effective dose of the active ingredient.
• the metering valve assembly comprises a ferrule having an aperture formed therein, a body molding attached to the ferrule which houses the metering chamber, a stem consisting of a core and a core extension, an inner- and an outer-seal around the metering chamber, a spring around the core, and a gasket to prevent leakage of propellant through the valve.
• the gasket seal and the seals around the metering valve may comprise elastomeric material such as EPDM, chlorobutyl rubber, bromobutyl rubber, butyl rubber, or neoprene. EPDM rubbers are particularly preferred.
• the metering chamber, core, and core extension are manufactured using suitable materials such as stainless steel, polyesters (e.g. polybutyleneterephthalate (PBT)), or acetals.
• the spring is manufactured in stainless steel eventually including titanium.
• the ferrule may be made of a metal, for example aluminum, aluminum alloy, stainless steel or anodized aluminum. Suitable valves are available from manufacturers such as Valois, Bespak plc and 3M-Neotechnic Ltd.
• the pMDI is actuated by a metering valve capable of delivering a volume of between 25 to 100 ⁇ l, preferably between 40 to 70 and optionally about 50 ⁇ l, or about 63 ⁇ l per actuation.
• Suitable channelling devices comprise, for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the mouth of a patient e.g. a mouthpiece actuator.
• the valve stem is seated in a nozzle block which has an orifice leading to an expansion chamber.
• the expansion chamber has an exit orifice which extends into the mouthpiece.
• Actuator (exit) orifices having a diameter in the range 0.15 to 0.45 mm and a length from 0.30 to 1.7 mm are generally suitable.
• an orifice having a diameter from 0.2 to 0.44 mm is used, e.g. 0.22, 0.25, 0.30, 0.33, or 0.42 mm.
• actuator orifices having a diameter ranging from 0.10 to 0.22 mm, in particular from 0.12 to 0.18 mm, such as those described in WO 03/053501.
• the use of said fine orifices may also increase the duration of the cloud generation and hence, may facilitate the coordination of the cloud generation with the slow inspiration of the patient.
• the MDI product in case the ingress of water into the formulation is to be avoided, it may be desired to overwrap the MDI product in a flexible package capable of resisting water ingress. It may also be desirable to incorporate a material within the packaging which is able to adsorb any propellant and co-solvent which may leak from the canister (e.g. a molecular sieve).
• a material within the packaging which is able to adsorb any propellant and co-solvent which may leak from the canister (e.g. a molecular sieve).
• the MDI device filled with the formulation of the present invention may be utilized together with suitable auxiliary devices favoring the correct use of the inhaler.
• Said auxiliary devices are commercially available and, depending on their shape and size, are known as “spacers”, “reservoirs” or “expansion chambers”. VolumaticTM is, for instance, one of the most widely known and used reservoirs, while AerochamberTM is one of the most widely used and known spacers.
• a suitable expansion chamber is reported for example in WO 01/49350.
• the formulation of the present invention may also be used with common pressurized breath-activated inhalers, such as those known with the registered names of Easi-BreatheTM and AutohalerTM.
• the efficacy of an MDI device is a function of the dose deposited at the appropriate site in the lungs. Deposition is affected by the aerodynamic particle size distribution of the formulation which may be characterised in vitro through several parameters.
• the aerodynamic particle size distribution of the formulation of the present invention may be characterized using a Cascade Impactor according to the procedure described in the European Pharmacopoeia 6 th edition, 2009 (6.5), part 2.09.18.
• An Apparatus E operating at a flow rate range of 30 l/minute to 100 l/minute or an Apparatus D-Andersen Cascade Impactor (ACI)-, operating at a flow rate of 28.3 l/minute.
• Deposition of the drug on each ACI plate is determined by high performance liquid chromatography (HPLC).
• the following parameters of the particles emitted by a pressurized MDI may be determined:
• the solutions of the present invention are capable of providing, upon actuation of the pMDI device in which they are contained, a total FPF higher than 40%, preferably higher than 50%, more preferably higher than 60%.
• the formulations of the present invention are capable of providing, upon actuation, a fraction higher than or equal to 30% of emitted particles of diameter equal to or less than 1.1 microns as defined by the content stages S6-AF of an Andersen Cascade Impactor, relative to the total fine particle dose collected in the stages S3-AF of the impactor.
• the fraction of emitted particles of diameter equal to or less than 1.1 microns is higher than or equal to 40%, more preferably higher than 50%, even more preferably higher than 60%, most preferably higher than 70%.
• a method of filling an aerosol inhaler with a composition of the present invention there is provided a method of filling an aerosol inhaler with a composition of the present invention.
• Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large-scale batches for the commercial production of filled canisters.
• a first method comprises:
• An alternative method comprises:
• a further alternative method comprises:
• oxygen is substantially removed from the headspace of the aerosol canister using conventional techniques in order to further stabilize the formoterol component, especially at higher acid concentrations.
• Purging can be achieved by vacuum crimping or by using propellant, for instance.
• the second filling method described above is modified to incorporate an oxygen purge into step (c) by vacuum crimping.
• the packaged formulations of the present invention are stable for extended periods of time when stored under normal conditions of temperature and humidity.
• the packaged formulations are stable for at least 6 months at 25° C. and 60% RH, more preferably for at least 1 year, most preferably for at least 2 years. Stability is assessed by measuring content of residual active ingredient.
• a “stable” formulation as defined herein means one retaining at least about 85%, preferably at least about 90%, and most preferably at least about 95% of residual content of each active ingredient at a given time point, as measured by HPLC-UV VIS.
• the optimized stable formulations meet the specifications required by the ICH Guideline Q1B or CPMP/QWP/122/02 Rev.1 relevant for drug product stability testing for the purposes of drug registration.
• the combination product compositions of the present invention may be used for prophylactic purposes or therapeutic purposes or for symptomatic relief of a wide range of conditions, and in one aspect the invention therefore relates to use of any of these pharmaceutical compositions as a medicament.
• the combination products of the present invention are useful in the prevention or treatment of many respiratory disorders, such as asthma of all types and chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• the present invention relates to a method of preventing or treating a respiratory disease, such as COPD, comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to the present invention.
• a respiratory disease such as COPD
• the present invention also provides the use of the pharmaceutical compositions of the present invention for the therapeutic or palliative treatment or prevention of respiratory diseases and their symptoms.
• Respiratory disorders for which use of the pharmaceutical compositions of the present invention may also be beneficial are those characterized by obstruction of the peripheral airways as a result of inflammation and presence of mucus, such as chronic obstructive bronchiolitis, chronic bronchitis, emphysema, acute lung injury (ALI), cystic fibrosis, rhinitis, and adult or acute respiratory distress syndrome (ARDS).
• mucus such as chronic obstructive bronchiolitis, chronic bronchitis, emphysema, acute lung injury (ALI), cystic fibrosis, rhinitis, and adult or acute respiratory distress syndrome (ARDS).
• the residual content of active ingredient was measured using standard chromatographic protocols.
• BDP and GLY can contents were not significantly affected by time and temperature.
• formoterol fumarate can content was highly dependent on storage conditions: the % residue with respect to time zero decreases with time and temperature. After 3 months at +30° C./75% RH, the % residue had reached 92.5%; after 3 months at +40° C./75% RH, it had decreased to 88.6%.
• Table 3 With regard to the double combination of FF+GLY, see Table 3:
• the GLY component remained stable under all of the tested conditions.
• the formoterol fumarate can content was strongly dependent on time and temperature: after 3 months at +30° C./75% RH, it had dropped to 91.5%; after 3 months at +40° C./75% RH, it had decreased to 88.1%.
• the formoterol content in the FF+BDP double combination did not decrease rapidly over time under any of the different storage conditions.
• a double or triple combination product comprising glycopyrronium bromide and formoterol fumarate (and optionally beclometasone dipropionate) could be optimally stabilized for clinical and commercial purposes by inclusion of 1M HCl in an amount of between 0.191 and 0.234 ⁇ g/ ⁇ l, preferably between 0.19 and 0.23 ⁇ g/ ⁇ l, in a solution formulation that has been purged of oxygen.
• the current results confirm that a triple combination product comprising glycopyrronium bromide, formoterol fumarate and, optionally, beclometasone dipropionate could be optimally stabilized for clinical and commercial purposes by inclusion of 1M HCl in an amount of between 0.19 and 0.243 ⁇ g/ ⁇ l, preferably between 0.19 and 0.230 ⁇ g/ ⁇ l, in a solution formulation crimped without oxygen removal and between 0.19 and 0.243 when crimped with oxygen removal.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Dispersion Chemistry (AREA)
• Mechanical Engineering (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Otolaryngology (AREA)
• Pain & Pain Management (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Heart & Thoracic Surgery (AREA)
• Anesthesiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• External Artificial Organs (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=42107420

Family Applications (3)

Family Applications After (2)

Country Status (39)

Cited By (12)

Families Citing this family (18)

Citations (7)

Family Cites Families (34)

• 2010
  • 2010-12-22 WO PCT/EP2010/070479 patent/WO2011076843A2/en active Application Filing
  • 2010-12-22 SI SI201030654T patent/SI2515855T1/sl unknown
  • 2010-12-22 EP EP10799030.1A patent/EP2515855B3/en active Active
  • 2010-12-22 PE PE2012000865A patent/PE20121396A1/es not_active Application Discontinuation
  • 2010-12-22 CN CN201410289445.6A patent/CN104055765B/zh active Active
  • 2010-12-22 PE PE2016000787A patent/PE20160853A1/es unknown
  • 2010-12-22 GE GEAP201012756A patent/GEP20156311B/en unknown
  • 2010-12-22 JP JP2012545323A patent/JP5914354B2/ja active Active
  • 2010-12-22 SG SG2012046157A patent/SG181868A1/en unknown
  • 2010-12-22 KR KR1020177009412A patent/KR20170040392A/ko active Search and Examination
  • 2010-12-22 ES ES10799030T patent/ES2468840T7/es active Active
  • 2010-12-22 BR BR112012015337A patent/BR112012015337B8/pt active IP Right Grant
  • 2010-12-22 EA EA201290375A patent/EA021917B1/ru active Protection Beyond IP Right Term
  • 2010-12-22 MX MX2012006878A patent/MX2012006878A/es active IP Right Grant
  • 2010-12-22 MY MYPI2012002844A patent/MY156949A/en unknown
  • 2010-12-22 EA EA201590179A patent/EA027778B1/ru active Protection Beyond IP Right Term
  • 2010-12-22 PL PL10799030.1T patent/PL2515855T6/pl unknown
  • 2010-12-22 UA UAA201207626A patent/UA113832C2/uk unknown
  • 2010-12-22 DK DK10799030.1T patent/DK2515855T6/da active
  • 2010-12-22 TW TW099145166A patent/TWI495468B/zh active
  • 2010-12-22 AU AU2010334859A patent/AU2010334859A1/en not_active Abandoned
  • 2010-12-22 NZ NZ600790A patent/NZ600790A/en unknown
  • 2010-12-22 CN CN201080058048.8A patent/CN102665679B/zh active Active
  • 2010-12-22 RS RS20140338A patent/RS53391B2/sr unknown
  • 2010-12-22 PT PT107990301T patent/PT2515855E/pt unknown
  • 2010-12-22 AR ARP100104922A patent/AR079726A1/es not_active Application Discontinuation
  • 2010-12-22 CA CA2785321A patent/CA2785321C/en active Active
  • 2010-12-22 KR KR1020127015996A patent/KR101757951B1/ko active IP Right Grant
  • 2010-12-23 US US12/977,159 patent/US20110150782A1/en not_active Abandoned
• 2012
  • 2012-05-29 TN TNP2012000269A patent/TN2012000269A1/en unknown
  • 2012-06-01 CO CO12092198A patent/CO6541628A2/es unknown
  • 2012-06-14 MA MA34966A patent/MA33823B1/fr unknown
  • 2012-06-21 CL CL2012001705A patent/CL2012001705A1/es unknown
  • 2012-06-21 ZA ZA2012/04615A patent/ZA201204615B/en unknown
• 2013
  • 2013-02-15 HK HK13101936.0A patent/HK1174566A1/xx unknown
• 2014
  • 2014-05-29 CY CY20141100382T patent/CY1115116T1/el unknown
  • 2014-06-23 HR HRP20140582TT patent/HRP20140582T4/hr unknown
  • 2014-10-23 HK HK14110591A patent/HK1197036A1/xx unknown
• 2015
  • 2015-07-29 US US14/812,190 patent/US10159645B2/en active Active
• 2016
  • 2016-04-04 JP JP2016075136A patent/JP6283388B2/ja active Active
  • 2016-09-27 AU AU2016234895A patent/AU2016234895B2/en active Active
• 2017
  • 2017-12-22 CY CY2017047C patent/CY2017047I2/el unknown
  • 2017-12-29 FI FIEP10799030.1T patent/FI2515855T6/fi active
• 2018
  • 2018-01-05 HU HUS1800001C patent/HUS1800001I1/hu unknown
  • 2018-01-10 LU LU00060C patent/LUC00060I2/fr unknown
  • 2018-01-11 LT LTPA2018001C patent/LTC2515855I2/lt unknown
  • 2018-01-12 NL NL300923C patent/NL300923I2/en unknown
  • 2018-04-30 AU AU2018202998A patent/AU2018202998A1/en not_active Abandoned
  • 2018-08-01 IL IL260932A patent/IL260932B/en active IP Right Grant
  • 2018-10-16 US US16/161,427 patent/US11389401B2/en active Active
• 2019
  • 2019-08-02 AR ARP190102199A patent/AR115897A2/es not_active Application Discontinuation

Patent Citations (8)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events